GRANULES INDIA LTD.-$

Granules India Limited announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received the Establishment Inspection Report (EIR) from the US FDA for its Chantilly, Virginia facility. The facility received a Voluntary Action Indicated (VAI) classification following an inspection conducted from March 30 to April 3, 2026, where four Form 483 observations were issued. This facility is crucial to Granules' global manufacturing and supply network, with a focus on quality and regulatory compliance.

Granules India Ltd. clarified to the stock exchange regarding the significant increase in the volume of the company's security across exchanges. The company stated that it has made all necessary disclosures in a timely and transparent manner as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Granules India maintains that the increase in volume is purely market-driven and affirms its commitment to adhering to SEBI regulations.

Granules India Ltd. has released the transcript of its Q4 and financial year ended March 31, 2026, earnings conference call. The call, hosted by MUFG, discussed the company's financial and operational performance, strategic progress, including the GPI facility's performance and the acquisition of Senn. The company highlighted its shift towards more complex products and its growth in the U.S. generic market.

Granules India Ltd has submitted its Monitoring Agency Report for the quarter ended March 31, 2026, as required by SEBI regulations. The report, prepared by India Ratings & Research Private Limited, confirms that there was no deviation from the stated objects regarding the utilization of proceeds raised through the Company's Preferential Issue. This conclusion is based on management undertakings and a certificate from the Statutory Auditor, S.R. Batliboi & Associates LLP. The filing ensures compliance with Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Granules India Ltd. has announced July 30, 2026, as the record date for determining shareholders' eligibility for the final dividend for the financial year ending March 31, 2026. This decision is pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Granules India Ltd. announced strong financial results for Q4 FY26 and the full financial year ended March 31, 2026. For Q4 FY26, revenue from operations increased by 23% year-on-year to ₹14,706 Mn, while Profit After Tax (PAT) grew 33% year-on-year to ₹2,016 Mn. EBITDA for the quarter rose 40% to ₹3,521 Mn. For the full financial year FY26, revenue from operations was ₹53,656 Mn, a 20% increase YoY, and PAT stood at ₹5,950 Mn, up 19% YoY. The company reported an improved Return on Capital Employed (ROCE) of 17.6% in FY26 and a significant reduction in net debt by ₹3,040 Mn from Q4 FY25, bringing net debt to ₹4,021 Mn with a net debt to EBITDA ratio of 0.34x. North America contributed 72% of Q4FY26 revenue, with Europe at 17%.

Granules India Ltd has announced a change in its Senior Management Personnel (SMP). The Board, in its meeting held on April 29, 2026, designated Mr. Harsha Chigurupati, who is currently an Executive Director, as a Senior Management Personnel of the company. This change is effective from April 30, 2026. In his new capacity as SMP, Mr. Chigurupati will be responsible for key areas including Transformation & Information Technology, Project Management, and Leadership Hiring. This internal re-designation aims to strengthen the company's leadership in these critical functions.

Granules India Ltd's Board of Directors has approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The results were prepared in accordance with Indian Accounting Standards (Ind-AS). The company's statutory auditors, M/s. S R Batliboi & Associates LLP, have issued an unmodified opinion on both the standalone and consolidated financial results for the financial year. The board meeting, held on April 29, 2026, commenced at 11:00 AM and concluded at 12:30 PM, fulfilling the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Granules India Ltd's Board of Directors, at their meeting on April 29, 2026, approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The Board also recommended a final dividend of ₹1.75 per equity share (175%) for the financial year 2025-26. The record date for this dividend payment has been fixed as July 30, 2026. Additionally, the company announced that its 35th Annual General Meeting (AGM) will be held on Thursday, August 06, 2026.

Granules India Ltd has announced that its Board of Directors will convene on Wednesday, April 29, 2026. The primary agenda for this meeting is to consider and approve the audited financial results for the fourth quarter and the full financial year ended March 31, 2026. Additionally, the Board will discuss and potentially recommend a final dividend for the financial year 2025-26. In light of this upcoming Board Meeting, the insider trading window for the company's securities will remain closed until Friday, May 01, 2026.